摘要
背景:出血性转化(HT)是急性缺血性卒中后常见且天然的并发症。 目前唯一经FDA批准的急性缺血性卒中治疗是用重组组织纤溶酶原激活物(rtPA)快速再灌注。 虽然已被证明可以夸大HT的风险和严重程度,并与增加的发病率和死亡率相关联。 目的:本研究的目的是讨论出血性转化的多因素病理生理学,有希望的介入治疗目标和药物治疗方案。 结果和结论:了解HT对于通过再灌注治疗恢复缺血性脑的脑血流是必不可少的,而不引起这种并发症和额外的脑损伤。 因此,需要预防和治疗HT的方法。 虽然实验研究显示出有希望的结果,但临床翻译仍然不能令人满意。
关键词: 脑缺血,转化,出血性转化,预防,中风,治疗。
图形摘要
Current Drug Targets
Title:Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Volume: 18 Issue: 12
关键词: 脑缺血,转化,出血性转化,预防,中风,治疗。
摘要: Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality.
Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.Export Options
About this article
Cite this article as:
Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation, Current Drug Targets 2017; 18 (12) . https://dx.doi.org/10.2174/1389450117666160818115850
DOI https://dx.doi.org/10.2174/1389450117666160818115850 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages
Central Nervous System Agents in Medicinal Chemistry Novel Penetrating Cations for Targeting Mitochondria
Current Pharmaceutical Design Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Purinergic Receptors and Pain
Current Pharmaceutical Design Biomimetic Synthetic Self-Assembled Hydrogels for Cell Transplantation
Current Topics in Medicinal Chemistry Underlying Mechanisms and Potential Therapeutic Molecular Targets in Blood-Brain Barrier Disruption after Subarachnoid Hemorrhage
Current Neuropharmacology COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Current Pharmaceutical Design COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Effect of Edaravone on MicroRNA Expression in Exosomes after Hepatic Ischemia-reperfusion Injury
Current Molecular Pharmacology Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology